Mesothelioma: Overview of Technical, Immunochemical and Pathomorphological Diagnosing Aspects

Author:

Minajeva Ave,Saranova Diana

Abstract

For the clinicians with non-pathology background, first encountering the patients with pleural or peritoneal effusions, mesothelioma is only one statistically rare but clinically significant option of many differential diagnoses. This review aims to help the clinicians and broad life science audiences to understand step by step the possibilities and shortcomings of pathological diagnosing of mesothelioma, including the basic technical requirements. The first cytomorphology evaluation of pleural and peritoneal effusions in routinely stained smears enables in most cases only to identify cells suspicious for malignancy. The recent guidelines of epithelioid mesothelioma cytologic diagnosis and reporting emphasize immunochemistry (IC) in the cell blocks is mandatory whenever a diagnosis of malignancy is clinically entertained and/or cytologically suspected. The IC workup is challenging, since there is no fixed antibody panel, but multiple questions must be solved, such as 1) confirm the mesothelial or epithelial origin of isolated atypical cells and cell clusters; 2) delineate their benign or malignant nature; and 3) discriminate mesothelioma from other malignancies and metastatic disease. The rationale of the most widely clinically used IC markers is given and illustrated by the examples. The final confirmation of mesothelioma diagnosis and establishing its subtype and grade is possible only in the histological samples.

Publisher

IntechOpen

Reference68 articles.

1. Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, et al. The 2021 WHO classification of tumors of the pleura: Advances since the 2015 classification. Journal of Thoracic Oncology. 2022;17(5):608-622

2. Dacic S, de Perrot M, Gill RR, Hiroshima K, Klebe S, Nabeshima K. Mesothelioma in situ. In: Thoracic Tumours WHO, editor. Classification of Tumours. 5th ed. Lyon: WHO Classification of Tumours Editorial Board; 2021. pp. 200-201

3. Khoor A, Bironzo P, Bueno R, Novak AKSF. Localized plaural masothelioma. In: Thoracic Tumours WHO, editor. Classification of Tumours. 5th ed. Lyon: WHO Classification of Tumours Editorial Board; 2021. pp. 202-203

4. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes & Control. 2009;20(6):935-944

5. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: Indicators of change and insights into background rates. European Journal of Cancer Prevention. 2008;17(6):525-534

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3